跳转至内容
Merck
CN
  • Identification of a regulatory pathway governing TRAF1 via an arthritis-associated non-coding variant.

Identification of a regulatory pathway governing TRAF1 via an arthritis-associated non-coding variant.

Cell genomics (2023-11-29)
Qiang Wang, Marta Martínez-Bonet, Taehyeung Kim, Jeffrey A Sparks, Kazuyoshi Ishigaki, Xiaoting Chen, Marc Sudman, Vitor Aguiar, Sangwan Sim, Marcos Chiñas Hernandez, Darren J Chiu, Alexandra Wactor, Brian Wauford, Miranda C Marion, Maria Gutierrez-Arcelus, John Bowes, Stephen Eyre, Ellen Nordal, Sampath Prahalad, Marite Rygg, Vibeke Videm, Soumya Raychaudhuri, Matthew T Weirauch, Carl D Langefeld, Susan D Thompson, Peter A Nigrovic
摘要

TRAF1/C5 was among the first loci shown to confer risk for inflammatory arthritis in the absence of an associated coding variant, but its genetic mechanism remains undefined. Using Immunochip data from 3,939 patients with juvenile idiopathic arthritis (JIA) and 14,412 control individuals, we identified 132 plausible common non-coding variants, reduced serially by single-nucleotide polymorphism sequencing (SNP-seq), electrophoretic mobility shift, and luciferase studies to the single variant rs7034653 in the third intron of TRAF1. Genetically manipulated experimental cells and primary monocytes from genotyped donors establish that the risk G allele reduces binding of Fos-related antigen 2 (FRA2), encoded by FOSL2, resulting in reduced TRAF1 expression and enhanced tumor necrosis factor (TNF) production. Conditioning on this JIA variant eliminated attributable risk for rheumatoid arthritis, implicating a mechanism shared across the arthritis spectrum. These findings reveal that rs7034653, FRA2, and TRAF1 mediate a pathway through which a non-coding functional variant drives risk of inflammatory arthritis in children and adults.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
Anti-TRAF1 Antibody, clone 1F3, clone 1F3, from rat